Tag: Nasdaq:IMCR

Immunocore to report second quarter 2025 financial results and host call on August 7, 2025

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, July 31, 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report second quarter financial results, before the US markets open on Thursday, August 7, 2025.

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTagsNasdaq:IMCR

SmartVascular Dx™ Test Elevates Vascular Risk Detection in the Northeast & Partnership with MOMS

ThreeD Capital Inc. Completes Private Placement Financing

ABRDN INCOME CREDIT STRATEGIES FUND ANNOUNCES “AT-THE-MARKET” EQUITY OFFERING PROGRAM

Tag: Nasdaq:IMCR

Immunocore to report second quarter 2025 financial results and host call on August 7, 2025

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us